Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

Journal of Viral Hepatitis

Volumn 14, Issue 11, 2007, Pages 767-774

  Pan, X P ^a   Li, L J ^a   Du, W B ^a   Li, M W ^a   Cao, H C ^a   Sheng, J F ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Genotype; Lamivudine; Lamivudine resistant variants; Mutational patterns; Precore core promoter mutations; Tyrosine methionine aspartate aspartate (YMDD) mutant

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA DIRECTED DNA POLYMERASE ALPHA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; ENZYME BLOOD LEVEL; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENETICS; VIRUS GENE;

ADULT; AGED; ALANINE TRANSAMINASE; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SEQUENCE ALIGNMENT;

EID: 35248853310     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00869.x     Document Type: Article

References (47)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997 337 : 1733 1745.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993 262 : 369 370.
3. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 341 : 1256 1263.
4. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 339 : 61 68.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 333 : 1657 1661.
6. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 117.
7. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996 24 : 714 717.
8. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998 27 : 1670 1677.
9. Ono-Nita SK, Kato N, Shiratori Y et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999 29 : 939 945.
10. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 24 : 711 713.
11. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001 34 : 785 791.
12. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997 349 : 20 22.
13. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001 33 : 1527 1532.
14. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999 30 : 567 572.
15. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002 37 : 366 369.
16. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000 33 : 998 1002.
17. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002 36 : 1425 1430.
18. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002 36 : 303 304.
19. Ben-Ari Z, Daudi N, Klein A et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003 98 : 151 159.
20. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003 38 : 1267 1273.
21. Zollner B, Petersen J, Puchhammer-Stockl E et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004 39 : 42 50.
22. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001 34 : 1225 1241.
23. Usuda S, Okamoto H, Iwanari H et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999 80 : 97 112.
24. Sun J, Wang Z, Ma S et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol 2005 75 : 391 398.
25. Abe A, Inoue K, Tanaka T et al. Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol 1999 37 : 2899 2903.
26. He ML, Wu J, Chen Y, Lin MC, Lau GK, Kung HF. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun 2002 295 : 1102 1107.
27. Jun-Bin S, Zhi C, Wei-Qin N, Jun F. A quantitative method to detect HBV cccDNA by chimeric primer and real-time polymerase chain reaction. J Virol Methods 2003 112 : 45 52.
28. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998 339 : 61 68.
29. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000 119 : 172 180.
30. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enchances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001 33 : 1527 1532.
31. Tian Y, Du SC, Zhang R, Wei L, Chen Y, Han JD. YVDD is the primary symbol of gene mutation in hepatitis B patients treated with lamivudine. Zhonghua Gan Zang Bing Za Zhi 2005 13 : 455 456.
32. Akuta N, Suzuki F, Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003 38 : 315 321.
33. Suzuki F, Tsubota A, Arase Y et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003 46 : 182 189.
34. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 2005 43 : 72 77.
35. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001 357 : 934 935.
36. Zollner B, Stoehr A, Plettenberg A et al. In vivo dynamics and pathogenicity of wild type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note. J Clin Virol 2000 17 : 183 188.
37. Gutfreund KS, Williams M, George R et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000 33 : 469 475.
38. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997 26 : 1393 1395.
39. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998 339 : 61 68.
40. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 32 : 828 834.
41. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001 12 : 67 71.
42. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003 23 : 5 20.
43. Chen RY, Edwards R, Shaw T et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003 37 : 27 35.
44. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000 31 : 1037 1044.
45. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996 70 : 5845 5851.
46. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004 78 : 8524 8535.
47. Akuta N, Suzuki F, Kobayashi M et al. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. J Med Virol 2003 71 : 504 510.